Xencor, Inc Equity Securities, FV-NI
Xencor, Inc (XNCR) had Equity Securities, FV-NI of $78.64 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Short-Term Investments
us-gaap:EquitySecuritiesFvNi · last filed 2026-08-05
- 2026-06-30: Equity Securities, FV-NI $78.64M.
- 2026-03-31: Equity Securities, FV-NI $60.57M.
- 2025-12-31: Equity Securities, FV-NI $112.50M.
- 2025-09-30: Equity Securities, FV-NI $84.26M.
| Period end | Equity Securities, FV-NI |
|---|---|
| 2026-06-30 | $78.64M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $60.57M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $112.50M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $84.26M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $40.44M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $48.87M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $47.93M 10-K · filed 2026-02-25 |
| 2024-09-30 | $78.90M 10-Q/A · filed 2025-02-24 |
| 2024-06-30 | $28.27M 10-Q/A · filed 2025-02-24 |
| 2024-03-31 | $44.53M 10-Q/A · filed 2025-02-24 |
| 2023-12-31 | $42.21M 10-K · filed 2025-02-27 |
| 2023-09-30 | $28.97M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $39.99M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $39.71M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $42.43M 10-K/A · filed 2025-02-24 |
| 2022-09-30 | $32.18M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $26.89M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $33.43M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $36.86M 10-K · filed 2023-02-27 |
| 2021-09-30 | $47.58M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $45.23M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $6.14M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $5.30M 10-K · filed 2022-02-24 |
| 2020-09-30 | $5.38M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $2.61M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $2.25M 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |